Patents by Inventor Kristen M. HEGE

Kristen M. HEGE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION
    Publication number: 20220175770
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Application
    Filed: July 20, 2021
    Publication date: June 9, 2022
    Inventors: Ellen FILVAROFF, Kristen M. HEGE, Shaoyi LI
  • Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
    Patent number: 11096940
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Kristen M. Hege, Shaoyi Li
  • TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION
    Publication number: 20200121676
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Application
    Filed: June 21, 2018
    Publication date: April 23, 2020
    Inventors: Ellen FILVAROFF, Kristen M. HEGE, Shaoyi LI
  • Methods for treating cancer using combination therapy
    Patent number: 9119854
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: September 1, 2015
    Assignee: Celgene Corporation
    Inventors: Rajesh Chopra, Kristen M. Hege
  • METHODS FOR TREATING CANCER USING COMBINATION THERAPY
    Publication number: 20140328832
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: CELGENE CORPORATION
    Inventors: Rajesh CHOPRA, Kristen M. HEGE